Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
Fate Therapeutics (NASDAQ: FATE) announced management will participate in the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.
Rhea-AI Summary
Fate Therapeutics (NASDAQ: FATE) announced management will participate in the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.
Management will join a fireside chat at 9:20 AM ET, host investor meetings, and provide a live webcast with an archived replay available for 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – FATE
In the Mar 4 session, FATE gained 5.84%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- March 9, 2026
- Leerink Partners 2026 Global Healthcare Conference
- Fireside chat time
- 9:20 AM ET
- Scheduled management fireside chat
- Webcast replay period
- 90 days
- Archived replay available on company website
- Current price
- $1.50
- Pre-news trading level
- 52-week high
- $1.9399
- Upper end of 52-week trading range
- 52-week low
- $0.6611
- Lower end of 52-week trading range
- Price vs 52-week high
- -22.68%
- Distance from 52-week high before this news
- Market cap
- $170,721,388
- Equity value prior to conference announcement
Historical Context
-
Q4 and 2025 results with strong cash and reduced operating expenses.
-
New-hire stock options and RSUs under Nasdaq inducement rule.
-
Equity awards to new hires via options and RSUs for recruitment.
-
Updated Phase 1 FT819 data and preclinical advances for FT836/FT839.
-
Participation in Piper Sandler healthcare conference with fireside chat.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
induced pluripotent stem cell medical
cellular immunotherapies medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat and host investor meetings at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.
Management will participate in a fireside chat at 9:20 AM ET on Monday, March 9. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 90 days on the Company’s website following the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.